A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma

[1]  C. Brennan,et al.  EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma , 2019, Journal of Neuro-Oncology.

[2]  O. Chinot,et al.  Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial , 2017, Oncotarget.

[3]  Andrew P. Stubbs,et al.  Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. , 2016, Cancer research.

[4]  R. Stupp,et al.  LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL , 2015 .

[5]  M. J. van den Bent,et al.  Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. , 2015, Neuro-oncology.

[6]  M. J. van den Bent,et al.  The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. , 2015, European journal of cancer.

[7]  J. Morales,et al.  Prognostic significance of the markers IDH1 and YKL40 related to the subventricular zone. , 2015, Folia neuropathologica.

[8]  C. Brennan,et al.  Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma , 2014, Clinical Cancer Research.

[9]  R. Vernhout,et al.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.

[10]  K. Aldape,et al.  Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution , 2013, Modern Pathology.

[11]  T. Cloughesy,et al.  Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy , 2013, Current Neurology and Neuroscience Reports.

[12]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[13]  M. Mrugala,et al.  Carboplatin and bevacizumab for recurrent malignant glioma. , 2012, Oncology letters.

[14]  A. Friedman,et al.  Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients , 2012, British Journal of Cancer.

[15]  I. Yang,et al.  CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme. , 2012, Neurosurgery clinics of North America.

[16]  R. Scienza,et al.  Serum YKL-40 following resection for cerebral glioblastoma , 2012, Journal of Neuro-Oncology.

[17]  H. Poulsen,et al.  Irinotecan and bevacizumab in recurrent glioblastoma multiforme , 2011, Expert opinion on pharmacotherapy.

[18]  R. Shao,et al.  A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers , 2011, Molecular Cancer Therapeutics.

[19]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[20]  P. Keegan,et al.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.

[21]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Wen,et al.  An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma , 2009, Journal of Neuro-Oncology.

[23]  M. Chamberlain.  BEVACIZUMAB FOR RECURRENT MALIGNANT GLIOMAS: EFFICACY, TOXICITY, AND PATTERNS OF RECURRENCE , 2009, Neurology.

[24]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[25]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[26]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[27]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[28]  L. Deangelis,et al.  YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas , 2006, Clinical Cancer Research.

[29]  J. Johansen.  Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. , 2006, Danish medical bulletin.

[30]  V. Tse,et al.  Recurrent glioblastoma multiforme: a review of natural history and management options. , 2006, Neurosurgical focus.

[31]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[32]  A. Brandes,et al.  How effective is BCNU in recurrent glioblastoma in the modern era? , 2004, Neurology.

[33]  M. member.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. , 2001 .

[34]  David M. Thomas,et al.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Wen,et al.  Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. , 1995, Neurosurgery.

[37]  H. Fine,et al.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[38]  N. Bleehen,et al.  An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. , 1987, British Journal of Cancer.

[39]  Jill S. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 , 2015, Neuro-oncology.

[40]  Michael Weller,et al.  Standards of care for treatment of recurrent glioblastoma--are we there yet? , 2013, Neuro-oncology.

[41]  L. Ricci-Vitiani,et al.  Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis , 2011, Cancer.

[42]  晏 小林,et al.  脳内出血で発症した転移性extraskeletal myxoid chondrosarcomaの1例 , 2008 .